2. Stem Cell/Wnt Cytoskeleton
  3. β-catenin Wnt Collagen
  4. PTD-DBM

PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PTD-DBM

PTD-DBM Chemical Structure

CAS No. : 1609454-11-6

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

PTD-DBM Related Antibodies

Top Publications Citing Use of Products

View All Wnt Isoform Specific Products:

View All Isoforms
Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing[1][2][3].

In Vitro

PTD-DBM (10 μM; 72 h) restores Wnt/β-catenin signaling and proliferation marker expression in PGD2-treated HaCaT cells[1].
PTD-DBM (2-10 μM; 24 h-2 d) activates Wnt/β-catenin signaling and promotes myofibroblast differentiation, collagen production, collagen gel contraction, and cell migration in human dermal fibroblasts in vitro in a concentration-dependent manner, with effects abolished by β-catenin knockdown or bosentan, and synergistically enhanced by co-treatment with Wnt3a[3].
PTD-DBM (2 μM; 2 d) synergistically enhances Wnt/β-catenin activation with Wnt3a in HaCaT keratinocytes, increasing β-catenin expression[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PTD-DBM Related Antibodies
In Vivo

PTD-DBM (10 mM; topical; every other day; 8 to 12 or 20 days post-depilation) restores PGD2-induced alopecia in C57BL/6N mice by reactivating Wnt/β-catenin signaling and hair follicle proliferation, recovering hair shaft length to control levels[1].
PTD-DBM (10 mM; topical; daily; 7 to 21 or 25 days post-wounding) restores PGD2-impaired wound-induced hair follicle neogenesis in C57BL/6N mice by reactivating Wnt/β-catenin signaling and regenerative markers, recovering neogenic follicle counts to control levels[1].
PTD-DBM (100 μM; topical; daily; 11 days) alone accelerates cutaneous wound healing and increases collagen production in mice, while PTD-DBM (100 μM + 500 mM VPA; topical; daily; 11 days) co-treatment with VPA synergistically enhances these effects, with no induction of oncogenic markers c-Myc or cyclin D1[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6N wild-type (7-week-old male; dorsal skin depilation-induced hair cycle synchronization, topical PGD2 exposure-induced hair growth suppression)[1]
Dosage: 10 mM
Administration: topical; every other day; 8 to 12 or 20 days post-depilation
Result: Restored PGD2-suppressed hair shaft length to levels comparable to untreated control mice.
Restored nuclear β-catenin fluorescence intensity and PCNA protein expression in skin tissues, which were reduced by PGD2 exposure.
Animal Model: C57BL/6N wild-type (3-week-old; full-thickness dorsal skin wound, topical PGD2 exposure-induced hair follicle regeneration suppression)[1]
Dosage: 10 mM
Administration: topical; daily; 7 to 21 or 25 days post-wounding
Result: Restored PGD2-suppressed neogenic hair follicle counts (measured via ALP staining) to levels comparable to untreated control mice.
Induced expression of WIHN markers (fgf9, keratin 17), as well as β-catenin and PCNA protein expression in wounded skin tissues, which were reduced by PGD2 exposure.
Animal Model: C3H mice (7-week-old male)[3]
Dosage: 100 μM (single-agent); 100 μM + 500 mM VPA (combination)
Administration: topical; daily; 11 days
Result: Accelerated cutaneous wound healing to a degree comparable to EGF treatment, reaching ~90% wound closure by day 12.
Increased β-catenin levels in wound tissue, and induced increases in keratin 14, collagen I, PCNA, and endothelin-1 expression in wound keratinocytes and fibroblasts.
Induced significantly greater increases in β-catenin, keratin 14, collagen I, PCNA, endothelin-1, and phosphorylated ERK in wound tissue compared to single-agent treatments or EGF.
Molecular Weight

3082.64

Formula

C124H225N61O28S2
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys
Sequence Shortening

RRRRRRRRGGGGRKTGHQICKFRKC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (32.44 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.3244 mL 1.6220 mL 3.2440 mL
5 mM 0.0649 mL 0.3244 mL 0.6488 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 0.3244 mL 1.6220 mL 3.2440 mL 8.1099 mL
5 mM 0.0649 mL 0.3244 mL 0.6488 mL 1.6220 mL
10 mM 0.0324 mL 0.1622 mL 0.3244 mL 0.8110 mL
15 mM 0.0216 mL 0.1081 mL 0.2163 mL 0.5407 mL
20 mM 0.0162 mL 0.0811 mL 0.1622 mL 0.4055 mL
25 mM 0.0130 mL 0.0649 mL 0.1298 mL 0.3244 mL
30 mM 0.0108 mL 0.0541 mL 0.1081 mL 0.2703 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PTD-DBM Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PTD-DBM1609454-11-6β-cateninWntCollagenBeta catenincutaneous woundHaCaT cellsandrogenetic alopeciaWnt/β-catenin pathwayDvlCXXC5CXXC5-Dvlhuman dermal fibroblastsC57BL/6N miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PTD-DBM
Cat. No.:
HY-P11112
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.